Chung S J, Chong S, Seth P, Jung C Y, Fung H L
Department of Pharmaceutics, School of Pharmacy, State University of New York, Buffalo.
J Pharmacol Exp Ther. 1992 Feb;260(2):652-9.
The pharmacological action of organic nitrate vasodilators [e.g., nitroglycerin (NTG)] is thought to be mediated through metabolic conversion to nitric oxide (NO); conversion leads to vasodilatation, whereas diminished conversion in chronic therapy may lead to pharmacological tolerance. The biochemical nature of this process, however, is poorly understood. Glutathione-S-transferases (GST) have been shown to metabolize organic nitrates in the liver, but it is not known whether these enzymes are involved in this pharmacologically relevant process. We, therefore, compared the activities of conversion of NTG to NO vs. those of GST in microsomal suspensions of bovine coronary artery smooth muscle tissue. A classical GST substrate, 1-chloro-2,4-dinitrobenzene, inhibited NO production in microsomes, suggesting possible involvement of GST in organic nitrate activation. However, GST activity derived from microsomes exhibited a different heat lability profile compared to that of NO generation. Known inhibitors of GST (viz., indomethacin and bromosulfophthalein) did not alter the NO-generating activity in microsomes. Glutathione was a critical cofactor for GST, but not for NO generation from NTG, and thiols other than glutathione (e.g., N-acetyl-L-cysteine and thiosalicylic acid) also could facilitate NO production. Moreover, comparison to a commercially available purified liver GST preparation showed that, at the same GST activity toward 1-chloro-2,4-dinitrobenzene, the microsomal incubation produced about 8 times more NO than the purified liver GST. Radiation inactivation analysis of the functional molecular sizes of GST and the NO-producing enzyme(s) suggested that the enzymes were of different molecular weights (54 kD and 160 kD, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
有机硝酸酯类血管扩张剂[如硝酸甘油(NTG)]的药理作用被认为是通过代谢转化为一氧化氮(NO)来介导的;这种转化会导致血管舒张,而长期治疗中转化减少可能会导致药理耐受性。然而,这一过程的生化本质却知之甚少。谷胱甘肽-S-转移酶(GST)已被证明可在肝脏中代谢有机硝酸酯,但尚不清楚这些酶是否参与了这一与药理学相关的过程。因此,我们比较了牛冠状动脉平滑肌组织微粒体悬浮液中NTG转化为NO的活性与GST的活性。一种经典的GST底物1-氯-2,4-二硝基苯抑制了微粒体中NO的产生,提示GST可能参与有机硝酸酯的活化。然而,微粒体来源的GST活性与NO生成的热稳定性曲线不同。已知的GST抑制剂(即吲哚美辛和溴磺酞)并未改变微粒体中NO生成活性。谷胱甘肽是GST的关键辅因子,但不是NTG产生NO所必需的,除谷胱甘肽外的其他硫醇(如N-乙酰-L-半胱氨酸和硫代水杨酸)也可促进NO的产生。此外,与市售纯化肝GST制剂相比,在对1-氯-2,4-二硝基苯具有相同GST活性时,微粒体孵育产生的NO比纯化肝GST多约8倍。对GST和产生NO的酶的功能分子大小进行辐射失活分析表明,这两种酶的分子量不同(分别为54 kD和160 kD)。(摘要截短于250字)